Novel Chemotherapies More Often Used On- Than Off-Label Monthly Prescribing Reference ... maximize the likelihood of an optimal risk-benefit ratio for both individual patients and the system as a whole." One author disclosed financial ties to Genentech; a second author is an economic expert for plaintiffs in suit against the ... |
